-
公开(公告)号：US11635436B2
公开(公告)日：2023-04-25
申请号：US16608147
申请日：2018-04-24
IPC分类号： G01N33/68 , G01N21/33 , G01N21/64 , G01N33/52 , C07C309/65 , C07C309/73
摘要： The present invention relates to compositions and methods for determining the absolute configuration of D/L-cysteine and/or the enantiomeric composition of cysteine and/or the concentration of total cysteine in a sample. Uses of the composition and method are also described.
-
2.发明申请公开(公告)号：US20220305031A1
公开(公告)日：2022-09-29
申请号：US17618302
申请日：2020-06-11
发明人： Robert I. GLAZER , Moshe LEVI , Hongyan YUAN , Suman RANJIT
IPC分类号： A61K31/575 , A61K31/337 , A61K31/704 , A61K31/513 , A61K31/675 , A61K33/243 , A61K31/282 , A61K31/395 , A61K31/7068 , A61K31/475 , A61P35/00
摘要： Aspects of the technology described herein relate to a method of treating a malignancy in a subject. This method involves selecting a subject having a malignancy and administering dimethyl-3-beta-hydroxy-cholenamide (DMHCA) or derivative thereof to the subject in an amount effective to treat the malignancy. Methods of reducing malignancy-associated fibrosis in a subject and pharmaceutical combinations comprising (i) DMHCA or derivative thereof and (ii) one or more immune checkpoint inhibitors are also disclosed.
-
公开(公告)号：US20220282318A1
公开(公告)日：2022-09-08
申请号：US17630424
申请日：2020-07-30
发明人： Yun-Ling ZHENG
IPC分类号： C12Q1/6841 , G01N21/64 , G06T7/00
摘要： Provided are methods and compositions useful for assessing the length of telomeres. The disclosed methods and compositions are amenable to performance as a high-throughput method to assess telomere length (TL) and TL constitution using genomic DNA. Also provided are methods for diagnosing a telomere-related condition or disease in a subject, assessing general health and/or aging of a subject, establishing a relationship between telomere constitution and cancer and/or aging-related disease, assessing exposure to harmful substances and/or stresses of a subject, assessing response to a drug or drugs treatment of a subject, assessing disease risk of a subject, and assessing clinical outcome of a subject who is suffering from a disease/diseases. The methods are useful in studies of individuals and populations.
-
公开(公告)号：US20220249481A1
公开(公告)日：2022-08-11
申请号：US17659274
申请日：2022-04-14
发明人： Charbel Moussa
IPC分类号： A61K31/506 , A61K45/06 , A61K31/496
摘要： Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.
-
公开(公告)号：US11374269B2
公开(公告)日：2022-06-28
申请号：US17145482
申请日：2021-01-11
发明人： YuYe J. Tong , Eric G. Sorte
IPC分类号： H01M10/48 , H01M10/0525 , H01M4/58 , H01M4/587 , H01M4/66 , G01N24/08 , G01R33/46 , G01R33/36 , H01M8/04298 , G01R33/345 , H01M50/411
摘要： Provided are batteries and fuel cells incorporating a stripline detector for use in nuclear magnetic resonance (NMR). The stripline batteries and fuel cells can be used for in situ NMR measurement of battery or fuel cell chemistry. Also provided are methods for measuring in situ battery and fuel cell NMR using the stripline batteries and fuel cells of the invention.
-
公开(公告)号：US11373734B2
公开(公告)日：2022-06-28
申请号：US14401633
申请日：2013-05-20
IPC分类号： G06F16/00 , G16B50/00 , G06F16/248 , G06F16/21 , G16H70/40 , G16B50/20 , H04L67/10 , G16B45/00
摘要： The present invention provides a method for populating and searching a drug informatics database that includes receiving unprocessed data associated with a chemical compound from one or more data sources. The unprocessed data is parsed into a plurality of data objects based on a categorization associated with each of the data objects. Additional information, such as explanatory notes, is identified and associated with at least one of the data objects. The data objects are stored in entries within a data structure, where the data structure is searchable based on one or more of the data objects. A query for data associated with a chemical compound is received at a drug informatics database. The drug informatics database is then searched for data associated with the chemical compound and the search results are provided to a user.
-
公开(公告)号：US20220113298A1
公开(公告)日：2022-04-14
申请号：US17274128
申请日：2019-09-09
发明人： Anton Wellstein , Ghada M. Sharif , Makarand Paranjape , Leon Der
摘要： Systems and methods for characterizing cancer cells are disclosed. In certain embodiments, the systems and methods involve coating a first chamber with ECM material and adding a first plurality of cells to the first chamber, adding media to a second chamber, and adding a second plurality of cells and media to a third chamber. The first, second, and third chambers are then clipped together to form a chamber array. The chamber array is mounted to an electric cell impedance sensing reader and impedance readouts of cell invasion are collected from the electric array at time intervals. Cells detected to invade into the second chamber are extracted and characterized.
-
公开(公告)号：US20220113247A1
公开(公告)日：2022-04-14
申请号：US17275471
申请日：2019-09-11
摘要： The present invention relates to an analytical method that includes providing a sample potentially containing a chiral analyte that can exist in stereoisomeric forms, and providing a probe selected from the group consisting of metal salts. The sample is contacted with the probe under conditions that permit coordination of the probe to the analyte, if present in the sample; and, based on any coordination that occurs, the absolute configuration of the analyte in the sample, and/or the concentration of the analyte in the sample, and/or the enantiomeric composition of the analyte in the sample is/are determined.
-
公开(公告)号：US11278551B2
公开(公告)日：2022-03-22
申请号：US16493882
申请日：2018-03-15
发明人： Jill P. Smith , Louis Weiner , Sandra Jablonski , Sandeep Nadella , Shangzi Wang
IPC分类号： A61K31/5513 , A61P35/00 , A61K31/198 , C07K16/28
摘要： Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.
-
公开(公告)号：US11278522B2
公开(公告)日：2022-03-22
申请号：US16927544
申请日：2020-07-13
摘要： Previous studies (Xiao et al., 2001) have identified two metabolites of methadone, EMDP (2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline) and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine), which are considered to be inactive at opiate receptors, as relatively potent noncompetitive channel blockers of α3β4 nAChRs. We have now evaluated these compounds in rats and mice in preclinical behavioral models predictive of potential anxiolytic and antidepressant efficacy. We found that EMDP, but not EDDP, displayed robust effects predictive of anxiolytic and antidepressant efficacy without significant effects on locomotor activity. Moreover, EMDP at behaviorally active doses, unlike mecamylamine, did not produce eyelid ptosis, suggesting it may produce fewer autonomic side effects than mecamylamine. Thus, the methadone metabolite EMDP may represent a novel therapeutic avenue for the treatment of some affective disorders.
-
-
-
-
-
-
-
-
-
搜索结果
747 条记录 (耗时 0.033 秒)